Organon & Co. (NYSE:OGN) Given Consensus Rating of “Reduce” by Analysts

Organon & Co. (NYSE:OGN) has been given a consensus rating of “Reduce” by the seven brokerages that are covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $11.40.

OGN has been the subject of a number of recent analyst reports. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 14th. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. BNP Paribas Exane reissued a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Weiss Ratings upgraded shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th.

Organon & Co. Stock Up 0.1%

Organon & Co. stock traded up $0.01 during mid-day trading on Friday, reaching $13.56. The stock had a trading volume of 1,508,001 shares, compared to its average volume of 2,268,647. Organon & Co. has a one year low of $5.69 and a one year high of $13.60. The company has a 50-day moving average price of $13.27 and a two-hundred day moving average price of $9.53. The company has a market capitalization of $3.56 billion, a price-to-earnings ratio of 14.59, a PEG ratio of 1.25 and a beta of 1.54. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.42.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.02 earnings per share. On average, analysts expect that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Investors of record on Monday, May 11th were paid a dividend of $0.02 per share. The ex-dividend date was Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s payout ratio is 8.60%.

Insiders Place Their Bets

In other news, SVP Lynette Holzbaur bought 26,448 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The stock was bought at an average price of $13.35 per share, with a total value of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This represents a 100.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.62% of the company’s stock.

Hedge Funds Weigh In On Organon & Co.

A number of hedge funds have recently made changes to their positions in OGN. Foster Dykema Cabot & Partners LLC bought a new stake in Organon & Co. during the 3rd quarter valued at approximately $29,000. Farther Finance Advisors LLC lifted its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new position in Organon & Co. during the 4th quarter valued at $44,000. Kestra Advisory Services LLC bought a new stake in Organon & Co. during the 4th quarter valued at about $47,000. Finally, Empowered Funds LLC bought a new position in Organon & Co. in the 4th quarter worth about $74,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.